Discovery and SAR of a Novel Selective and Orally Bioavailable Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 1B

DOI Web Site 被引用文献2件
  • Henrik Sune Andersen
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Ole H. Olsen
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Lars F. Iversen
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Anette L. P. Sørensen
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Steen B. Mortensen
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Michael S. Christensen
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Sven Branner
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Thomas K. Hansen
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Jesper F. Lau
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Lone Jeppesen
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Edmond J. Moran
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Jing Su
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Farid Bakir
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Luke Judge
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Manou Shahbaz
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Tassie Collins
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Todd Vo
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Michael J. Newman
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • William C. Ripka
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009
  • Niels Peter H. Møller
    Departments of Medicinal Chemistry Research 1, 4, and 5 and Drug Metabolism, Health Care Discovery, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark, Departments of Protein Structure, Protein Design, and Signal Transduction, Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark, and Ontogen Corporation, 2325 Camino Vida Roble, Carlsbad, California 92009

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ